Oncology News Today

30/03/2026

📰 NEWS: Global experts suggest trial on anti-obesity drugs preventing obesity-related cancers

New research to be presented at this year’s European Congress on Obesity recommends a trial of around 5,000 high-risk participants to assess whether next-generation drugs can prevent obesity-related cancers in people with precursor conditions.

The expert group – comprising leading researchers from major obesity and cancer trials, alongside industry specialists and funders – is led by Dr Matthew Harris, supported by a Manchester–Leeds team. Representing their work at the European Congress on Obesity, they are joined by Professor Andrew Renehan of the Division of Cancer Sciences, The University of Manchester.

Read more: https://oncologynewstoday.co.uk/global-experts-suggest-trial-on-anti-obesity-drugs-preventing-obesity-related-cancers/

EASOobesity

New research to be presented at this year’s European Congress on Obesity recommends a trial of around 5,000 high-risk participants to assess whether next-generation obesity drugs can prevent obesity-related cancers in people with cancer precursor conditions.

27/03/2026

📰 NEWS: Study aims to spot pancreatic cancer in diabetes patients sooner

A research hub for a clinical study aiming to detect the early signs of pancreatic cancer in people with type 2 diabetes has been set up at Maidstone and Tunbridge Wells NHS Trust.

The study is led by Mr Zaed Hamady, a consultant surgeon specialising in pancreatic cancer at the University Hospital Southampton NHS Foundation Trust, and is run by the Southampton Clinical Trials Unit in collaboration with a US biotechnology company.

Kasha Hobbs, Diabetes Research Nurse, and Dr Samantha Anandappa, Lead for Diabetes and Endocrinology and Principal Investigator for the study (both pictured), have been delivering SAFE-D at the Trust.

Dr Anandappa said: “If shown to be effective, the new blood test could make a life-changing difference to thousands of people with newly diagnosed type 2 diabetes by supporting earlier pancreatic cancer diagnosis and enabling them to access treatment sooner.

“The findings may also help shape future screening programmes for high-risk groups, offering long term benefits for patient care.”

Read more:

A research hub for a clinical study aiming to detect the early signs of pancreatic cancer in people with type 2 diabetes has been set up at Maidstone and Tunbridge Wells NHS Trust.

26/03/2026

📰 NEWS: UK launches £5m next-generation cancer diagnostics programme to accelerate early detection and adoption

The Next Generation Cancer Diagnostics programme (NG-Dx), led by CPI and funded by the UK government’s Office for Life Sciences, will run for 18 months from January 2026. Designed as a pre-competitive programme, NG-Dx combines technical delivery with structured industry and public engagement to ensure innovation translates into clinically relevant, trusted and investable solutions.

Greig Rooney, Managing Director of Pharma and HealthTech at CPI, said: “Too many cancers are still diagnosed late, but earlier, more precise detection has the potential to transform outcomes for patients.

“NG-Dx brings industry, clinicians, patients and technology leaders together to accelerate the translation of promising science into diagnostics that can be used in healthcare systems."

Read more:

A new £5 million, UK-led programme has been launched to accelerate the development and adoption of next-generation cancer diagnostics, bringing industry, clinicians, patients and technology leaders together to overcome long-standing barriers to early detection.

26/03/2026

❗️ JOB ALERT: Health New Zealand - Te Whatu Ora is seeking Radiation Oncologists from the UK and Ireland to join multidisciplinary cancer services across New Zealand.

Working as a Radiation Oncologist in New Zealand offers a unique work-life balance in a clean, green, and safe environment. The country's healthcare system, particularly in Oncology, is recognised for its high standards and patient-centred care.

Radiation Oncologists have access to modern equipment and advanced technologies such as IMRT (Intensity-Modulated Radiation Therapy) and SBRT (Stereotactic Body Radiation Therapy).

APPLY NOW: https://oncologynewstoday.co.uk/jobs/radiation-oncologists-2/

25/03/2026

📰 NEWS: A new article looks at the benefits of integrating at-home care for both consultants and oncology patients.

For private consultants, integrating treatment at home is not about relinquishing control – it is about extending the reach of clinical practice.

It offers a way to deliver systemic anti-cancer therapies (SACT) and supportive care in a patients’ homes, under strict governance frameworks keeping the consultant, as the primary decision maker.

Read more: https://oncologynewstoday.co.uk/integrating-at-home-cancer-care-into-private-pathways/

Lloyds Clinical

24/03/2026

📰 NEWS: Royal Surrey research explores how AI could support radiologists in breast cancer screening

Researchers at Royal Surrey NHS Foundation Trust have helped lead major research showing that artificial intelligence (AI) could support radiologists in detecting breast cancer in routine screening mammograms, helping to ease pressure on NHS services.

The AIMs study analysed screening data from more than 125,000 women, making it the largest NHS study to date on AI in breast cancer screening. Findings were published this month in two companion papers in scientific journal, Nature Cancer.

The research was carried out in partnership with Imperial College London, Imperial College Healthcare NHS Trust, St George’s University Hospitals NHS Foundation Trust, and Google Research.

Read more:

Researchers at Royal Surrey NHS Foundation Trust have helped lead major research showing that artificial intelligence could support radiologists in detecting breast cancer in routine screening mammograms, helping to ease pressure on NHS services.

24/03/2026

❗️ JOB ALERT: Health New Zealand - Te Whatu Ora is seeking Medical Oncologists from the UK & Ireland to deliver high-quality systemic cancer care within hospital-based teams across New Zealand.

With an emphasis on collaboration between primary, secondary, and tertiary care, Medical Oncologists work closely with Surgeons, Radiologists, Pathologists, and Nurses to achieve the best outcomes for patients.

https://oncologynewstoday.co.uk/jobs/medical-oncologists-2/

23/03/2026

📰 NEWS: NICE publishes its first kidney cancer guideline, set to double biopsy rates and prevent hundreds of unnecessary surgeries each year

The National Institute for Health and Care Excellence (NICE) has published its first comprehensive clinical guideline on kidney cancer.

This landmark guideline follows years of campaigning, evidence gathering, and expert input from Kidney Cancer UK – whose Accord panel and clinical advisors worked closely with NHS England and NICE to demonstrate the need for clearer diagnostic standards, greater use of biopsy, and more consistent national care pathways.

Read more: https://oncologynewstoday.co.uk/nice-publishes-its-first-kidney-cancer-guideline-set-to-double-biopsy-rates-and-prevent-hundreds-of-unnecessary-surgeries-each-year/

Pictured: Andrew Greaves, General Manager at Kidney Cancer UK

The National Institute for Health and Care Excellence has published its first comprehensive clinical guideline on kidney cancer.

20/03/2026

📰 NEWS: New study reveals key enzyme as hidden driver of cancer stress responses

Researchers have identified the enzyme DHX8 as a crucial regulator of the stress‑response protein HSF1. This discovery deepens the scientific understanding of how cancers develop and resist treatment, and it may have potential to open new avenues for future drug development.

Co‑senior author Dr Paul Clarke, Group Leader in RNA Biology and Molecular Therapeutics at the ICR, said: “Our research reveals an entirely new layer of control in the stress‑response machinery on which cancer cells depend. DHX8 is not just an accessory splicing factor – it appears to be indispensable for the proper processing of HSF1 and a range of other transcripts that help tumour cells survive stressful conditions.”

Read more: https://oncologynewstoday.co.uk/new-study-reveals-key-enzyme-as-hidden-driver-of-cancer-stress-responses/

The Institute of Cancer Research Cancer Research UK

An important study has uncovered an unexpected molecular player that helps make cancer cells stress-resilient, thereby promoting the survival, growth and progression of tumours.

19/03/2026

📰 NEWS: First Hampshire Hospitals NHS Foundation Trust patient receives treatment in groundbreaking prostate cancer trial

Hampshire Hospitals is one of only five hospitals in the UK to recruit participants into this major global study, marking a significant milestone in the Trust’s contribution to prostate cancer research.

Unlike traditional treatments, Aquablation uses a robotic assisted, high-pressure waterjet to precisely remove prostate tissue. It avoids thermal damage and is designed to preserve key structures around the prostate, helping reduce the risk of life altering side effects commonly associated with treatments such as radical prostatectomy (complete prostate removal).

Read more: https://oncologynewstoday.co.uk/first-hampshire-hospitals-patient-receives-treatment-in-groundbreaking-prostate-cancer-trial/

Pictured: Hampshire Hospitals staff, including Consultant Urologist Dr Richard Hindley, with research trial patient Wayne Prosper

Hampshire Hospitals NHS Foundation Trust has successfully treated its first patient as part of a groundbreaking research trial exploring Aquablation therapy for localised prostate cancer.

18/03/2026

📰 NEWS: Cancer Research UK and NovalGen dose the first patient in the phase 1 trial of T-cell engager NVG-222

Cancer Research UK’s Centre for Drug Development (CDD) and NovalGen yesterday announced that the first patient has been dosed in a Phase 1 clinical trial evaluating NVG‑222, NovalGen’s next-generation self‑regulating T‑cell engager for the treatment of ROR1‑positive blood cancers.

The trial is sponsored and delivered by Cancer Research UK’s Centre for Drug Development and is led by Chief Investigator Will Townsend at UCLH - University College London Hospitals NHS Foundation Trust, where the first patient received treatment. Cancer Research Horizons is managing the commercial partnership between NovalGen and Cancer Research UK.

The study is enrolling patients across the UK with ROR1‑positive blood cancers and uses an adaptive design to optimise dose, treatment and biomarker strategies. Dosing of the first patient marks an important step in translating AutoRegulated immune therapies from the laboratory into clinical testing.

Read more:

Cancer Research UK’s Centre for Drug Development (CDD) and NovalGen yesterday announced that the first patient has been dosed in a Phase 1 clinical trial evaluating NVG‑222, NovalGen’s next-generation self‑regulating T‑cell engager for the treatment of ROR1‑positive blood cancers.

17/03/2026

❗️ JOB ALERT: Health New Zealand - Te Whatu Ora is seeking Medical Oncologists from the UK & Ireland to deliver high-quality systemic cancer care within hospital-based teams across New Zealand.

With an emphasis on collaboration between primary, secondary, and tertiary care, Medical Oncologists work closely with Surgeons, Radiologists, Pathologists, and Nurses to achieve the best outcomes for patients.

APPLY NOW: https://oncologynewstoday.co.uk/jobs/medical-oncologists/